techventurer
@impression4u6ss
India is seeing a surge in interest for GLP-1 treatments amidst growing diabetes and obesity. Eli Lilly introduced Mounjaro (tirzepatide) in March 2025 to tackle these issues, and Novo Nordisk is also gearing up for more developments.
0 reply
0 recast
0 reaction